PatientsVille.com Logo

INFLUENZA LIKE ILLNESS and Ranitidine

PatientsVille

INFLUENZA LIKE ILLNESS Symptoms and Causes

Mosquitoes are insects that live all over the world. There are thousands of different species of mosquitoes; about 200 of those live in the United States.

Female mosquitoes bite animals and humans and drink a very small amount of their blood. They need protein and iron from blood to produce eggs. After drinking blood, they find some standing water and lay their eggs in it. The eggs hatch into larvae, then pupae, and then they become adult mosquitos. The males live for about a week to ten days, and the females can live up to several weeks. Some female mosquitoes can hibernate in the winter, and they can live for months.

What health problems can mosquito bites cause?

Most mosquito bites are harmless, but there are times when they can be dangerous. The ways that mosquito bites can affect humans include

  • Causing itchy bumps, as an immune system response to the mosquito's saliva. This is the most common reaction. The bumps usually go away after a day or two.
  • Causing allergic reactions, including blisters, large hives, and in rare cases, anaphylaxis. Anaphylaxis is a severe allergic reaction that affects the whole body. It is a medical emergency.
  • Spreading diseases to humans. Some of these diseases can be serious. Many of them do not have any treatments, and only a few have vaccines to prevent them. These diseases are more of a problem in Africa and other tropical areas of the world, but more of them are spreading to the United States. One factor is climate change, which makes the conditions in some parts of the United States more favorable to certain types of mosquitoes. Other reasons include increased trade with, and travel to, tropical and subtropical areas.
Which diseases can mosquitoes spread?

Common diseases spread by mosquitoes include

  • Chikungunya, a viral infection that causes symptoms such as fever and severe joint pain. The symptoms usually last about a week, but for some, the joint pain may last for months. Most cases of chikungunya in the United States are in people who traveled to other countries. There have been a few cases where it has spread in the United States.
  • Dengue, a viral infection that causes a high fever, headaches, joint and muscle pain, vomiting, and a rash. Most people get better within a few weeks. In some cases, it can become very severe, even life-threatening. Dengue is rare in the United States.
  • Malaria, a parasitic disease that causes serious symptoms such as high fevers, shaking chills, and flu-like illness. It can be life-threatening, but there are drugs to treat it. Malaria is a major health problem in many tropical and subtropical areas of the world. Almost all cases of malaria in the United States are in people who traveled to other countries.
  • West Nile Virus (WNV), a viral infection that often has no symptoms. In those that do have symptoms, they are usually mild, and include fever, headache, and nausea. In rare cases, the virus can enter the brain, and it can be life-threatening. WNV has spread across the continental United States.
  • Zika Virus, a viral infection that often does not cause symptoms. One in five infected people do get symptoms, which are usually mild. They include a fever, rash, joint pain, and pinkeye. Besides being spread by mosquitoes, Zika can spread from mother to baby during pregnancy and cause serious birth defects. It can also spread from one partner to another during sex. There have been a few outbreaks of Zika in the southern United States.
How can I prevent mosquito bites?
  • Use an insect repellent when you go outdoors. Choose an Environmental Protection Agency (EPA)-registered insect repellent. They are evaluated to make sure they are safe and effective. Make sure that the repellant has one of these ingredients: DEET, picaridin, IR3535, oil of lemon eucalyptus, or para-menthane-diol. It is important to follow the instructions on the label.
  • Cover up. Wear long sleeves, long pants, and socks when outdoors. Mosquitoes may bite through thin fabric, so spray thin clothes with an EPA-registered repellent like permethrin. Don't apply permethrin directly to skin.
  • Mosquito-proof your home. Install or repair screens on windows and doors to keep mosquitoes out. Use air conditioning if you have it.
  • Get rid of mosquito breeding sites. Regularly empty standing water from your house and yard. The water could be in flowerpots, gutters, buckets, pool covers, pet water dishes, discarded tires, or birdbaths.
  • If you plan to travel, get information about the areas you will be going to. Find out whether there is a risk of diseases from mosquitoes, and if so, whether there is a vaccine or medicine to prevent those diseases. See a health care provider familiar with travel medicine, ideally 4 to 6 weeks before your trip.

Check out the latest treatments for INFLUENZA LIKE ILLNESS

INFLUENZA LIKE ILLNESS treatment research studies

Ranitidine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ranitidine Side Effects

Dyspnoea (125)
Anaphylactic Reaction (77)
Hypotension (71)
Diarrhoea (67)
Nausea (65)
Vomiting (62)
Urticaria (59)
Abdominal Pain (46)
Dizziness (43)
Malaise (43)
Cardiac Arrest (40)
Pain (39)
Loss Of Consciousness (37)
Fatigue (36)
Angioedema (35)
Confusional State (34)
Renal Failure Acute (33)
Pruritus (32)
Headache (32)
Chest Pain (31)
Abdominal Pain Upper (29)
Overdose (27)
Bradycardia (27)
Rash (27)
Pyrexia (25)
Hypersensitivity (24)
Dyspepsia (23)
Circulatory Collapse (23)
Chest Discomfort (22)
Erythema (21)
Thrombocytopenia (21)
Gastrooesophageal Reflux Disease (21)
Product Quality Issue (21)
Weight Decreased (20)
Burning Sensation (20)
Alanine Aminotransferase Increased (20)
Paraesthesia (20)
Cholelithiasis (20)
Dysgeusia (19)
Neutropenia (19)
Cough (19)
Flushing (19)
Hypertension (19)
Tubulointerstitial Nephritis (18)
Condition Aggravated (17)
Feeling Abnormal (17)
Depression (17)
Vision Blurred (17)
Agitation (16)
Heart Rate Increased (16)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Emotional Anxciety then chest pain, jaw pain on left side and headaches, I am not taking it no more. there has to be something else less tramatising to my system. It was bad enugh that i was at work when the emotional anxiety hit. not cool at all.

<strong>gracia por la informacion</strong>

*DONT_KNOW* guess that's an honest answer

Has there been any evidence linking ranitidine to lower back or hip problems?

Is Histac 150 a pain reliever for slip disc backache?

Will Marinol further damage, an already diseased liver

&lt;b&gt;Describe Your Diplopia from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here:&lt;/b&gt; In late winter of 2010 I had the regular flu shot and then the H1N1 shot about two days later. I normally wouldn't hav

Iama 41year old whitefemale After taking OTC delsym for a cough I developed pain in my back left side and severe fatigue, no energy. Thinking at first the illness just

<span style='color: #808080;'>&iquest;En qu&eacute; est&aacute;s pensando...?I'm a Spanish teenagerpatient of Cystic Fibrosis but I've never been very affected by the illness. In fact, I have quite normal living standards

<span style='color: #808080;'><b>Describe Your Guillain-Barre syndrome from INFLUENZA (SEASONAL) (FLUARIX) 2009 Experience Here: </b> <strong></strong><span style='color: #808080;'>To whom ever it may

<span style='color: #808080;'><b>Describe Your Henoch-Schonlein purpura from INFLUENZA (H1N1) (H1N1 (MONOVALENT) SANOFI) 2010 Experience Here:</b> Vicious headaches, rash on legs and trunk, transient, cystitis type fee

<span style='color: #808080;'><b>Describe Your Incorrect route of drug administration from INFLUENZA (SEASONAL) (FLUARIX) 2010 Experience Here:</b> as of 3/2711 still have pain wondering of it caused a frozen shoulder

<span style='color: #808080;'><b>Describe Your Injection site swelling from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here: I am 46, Female on discharge from hospital 12.6.10 10pm after treatment for acute diverticuli

<span style='color: #808080;'><b>Describe Your Neck pain from INFLUENZA (SEASONAL) (NO BRAND NAME) 2010 Experience Here:</b> Took 2010 flu shot on January 5, 2010. Fever ,chills and shaking 5 hours later. 12 hours late

<span style='color: #808080;'><b>Describe Your Pericarditis from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here: Received H1N1 vaccine mid October 2009. Three weeks later diagnosed with accute paricarditis. My age is

<span style='color: #808080;'><strong>Describe Your Drug exposure during pregnancy from INFLUENZA (SEASONAL) (FLUZONE) 2010 Experience Here:</strong> <span style='color: #000000;'><span style=

INFLUENZA LIKE ILLNESS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Comparison of Pantoprazole and Ranitidine in Dyspepsia
Condition: Dyspepsia
Interventions: Drug: Pantoprazole;   Drug: Ranitidine
Outcome Measures: Visual analogue scale score;   Need for additional drug
2 Recruiting TPI 287 in Breast Cancer Metastatic to the Brain
Condition: Breast Cancer
Interventions: Drug: TPI 287;   Drug: Dexamethasone;   Drug: Benadryl;   Drug: Ranitidine
Outcome Measure: Overall Response Rate
3 Recruiting Treatment of Orthostatic Hypotension in Autonomic Failure
Conditions: Autonomic Failure;   Orthostatic Hypotension
Interventions: Drug: Atomoxetine;   Drug: Acarbose;   Drug: Pyridostigmine Bromide;   Drug: Yohimbine;   Drug: Midodrine HCl;   Drug: placebo;   Drug: Modafinil;   Drug: Octreotide;   Other: water intake;   Drug: Diphenhydramine Hydrochloride;   Drug: Ranitidine HCL;   Drug: Tranylcypromine;   Drug: Ergotamine/ Caffeine;   Drug: Celecoxib;   Drug: Pseudoephedrine;   Drug: Methylphenidate;   Drug: Indomethacin;   Drug: Ibuprofen;   Drug: Oxymetazoline 0.05% nasal solution;   Dietary Supplement: Bovril;   Drug: Acetazolamide;   Drug: Rivastigmine tartrate;   Drug: Carbidopa/levodopa;   Device: Inflatable abdominal binder;   Device: inflatable abdominal binder (sham)
Outcome Measures: Increase in seated systolic blood pressure 1-hr post drug compared to baseline.;   Increase in standing time 1-hr post drug compared to baseline
4 Not yet recruiting The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux
Conditions: Eustachian Tube Dysfunction;   Laryngopharyngeal Reflux
Interventions: Drug: Omeprazole;   Drug: Ranitidine;   Drug: Pantoprazole;   Procedure: 24-Hour Diagnostic pH-Probe Test;   Procedure: Laryngoscopy
Outcome Measure: Evidence of laryngopharyngeal reflux in patients complaining of ear fullness/pressure/pain
5 Recruiting Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
Conditions: Pharmacokinetics;   Voriconazole
Intervention: Drug: Midazolam/Ranitidine/Esomeprazole
Outcome Measures: Voriconazole steady-state pharmacokinetics;   Voriconazole drug metabolizing enzyme activity
6 Recruiting Clinical Trial Corticoids For Empyema And Pleural Effusion In Children
Conditions: Parapneumonic Pleural Effusion;   Empyema
Interventions: Drug: Dexamethasone;   Drug: Placebo
Outcome Measures: time to resolution;   number of children with complications.;   Number of children with complications attributable to corticoids
7 Unknown  Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
Condition: Poisoning
Interventions: Drug: Chlorphenamine and Ranitidine;   Drug: Paracetamol
Outcome Measures: Attenuation of NAC induced vasodilatation by histamine antagonists (H1 and H2 antagonists) and/or paracetamol;   Inhibition of the inflammatory cascade contributes to a paracetamol mediated protective role against NAC adverse reactions.
8 Unknown  Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Condition: Dyspepsia
Intervention: Procedure: gastroscopic examination
Outcome Measures: Incidence of H. pylori Clarithromycin resistance gene;   Characteristic of H. pylori clarithromycin resistant gene mutation
9 Unknown  Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study
Condition: Helicobacter Pylori Infection
Interventions: Drug: Group A: NCA 600 mg+antibiotics;   Drug: Group B: antibiotic treatment (control)
Outcome Measure: To evaluate the usefulness of NAC as pre-treatment attempt associated with a culture-guided antibiotic therapy as rescue therapy after multi-attempts antibiotic failure
10 Recruiting Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
Condition: Glioblastoma Multiforme (GBM) WHO Grade IV
Intervention: Drug: Cabazitaxel
Outcome Measures: Response including SD, PR or CR determined by MRI (modified RANO criteria);   Overall and progression-free survival;   Safety and tolerability;   Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction);   Quality of life and neurocognitive functioning
11 Recruiting Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: carboplatin
Outcome Measures: To determine if patients have lower rates of hypersensitivity reactions compared to those treated with standard infusion carboplatin.;   Determine the rate of successful planned treatment completion of carboplatin in each group;   Perform a cost-identification analysis of extended infusion carboplatin to estimate the cost per hypersensitivity reaction prevented.;   Perform exploratory analyses to correlate hypersensitivity rate to history of atopy, prior drug allergies, number of lifetime platinum cycles, duration since last platinum, and concomitant chemotherapy agent.
12 Not yet recruiting Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Condition: Breast Neoplasms
Interventions: Drug: Vintafolide 2.5 mg;   Drug: Paclitaxel 80 mg/m^2;   Drug: Etarfolatide;   Drug: Folic acid;   Drug: Premedication for Paclitaxel
Outcome Measures: Progression Free Survival (PFS);   Objective Response Rate (Complete Response [CR] + Partial Response [PR]);   Clinical Benefit Rate (CR + PR + Stable Disease [SD] for >=6 months);   Overall Survival (OS)
13 Recruiting MAGIC vs. CROSS Upper GI. ICORG 10-14, V3
Conditions: Adenocarcinoma of the Oesophagus;   Adenocarcinoma of the Oesophago-gastric Junction;   Oesophageal Tumours;   Junctional Tumours;   Oesophageal Cancer
Interventions: Drug: Epirubicin;   Drug: Cisplatin;   Drug: 5 Flourouracil/ Capecitabine;   Radiation: (41.4 Gy/23 fractions);   Drug: Paclitaxel;   Drug: Carboplatin
Outcome Measure: Overall survival
14 Recruiting Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Condition: Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Copanlisib (BAY80-6946)
Outcome Measures: Adverse event collection;   Maximum tolerated dose, measured by adverse event profile;   Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed);   Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only);   Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15;   Number of patients with mutational status;   Tumor Response as measured by RECIST 1.1 criteria
15 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
Outcome Measures: Antitumor activity, as measured by tumor response rate of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer;   Time to progression;   Survival;   Overall survival;   Toxicity of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer
16 Unknown  Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
Conditions: Brain and Central Nervous System Tumors;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Biological: filgrastim;   Biological: lenograstim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: paclitaxel
Outcome Measures: Maximum tolerated dose of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (phase I);   Response rates (phase I);   Failure-free survival (phase I);   Utility of positron emission tomography scanning after Gem-TIP chemotherapy (phase I);   Degree of dose intensification achieved with Gem-TIP chemotherapy relative to a previous Medical Research Council study with TIP alone (phase II)